Using Human CD20-Transfected Murine Lymphomatous B Cells to Evaluate the Efficacy of Intravitreal and Intracerebral Rituximab Injections in Mice

Mineo, Jean-Franc ̧ois; Scheffer, A.; Karkoutly, C.; Nouvel, L.; Kerdraon, Olivier; Trauet, Jacques; Bordron, Anne; Dessaint, Jean-Paul; Labalette, Myriam; Berthou, Christian; Labalette, P.

doi:10.1167/iovs.07-1494

Cited by 38 publications

(25 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the murine 38C13 cell line expressing the human CD20 antigen has been used to evaluate the therapeutic potential of rituximab against intravenously injected disseminated tumors [43] and against central nervous system tumors [68]. The authors showed in the first case [43] that depletion of neutrophils, NK cells, and macrophages did not influence antibody efficacy, but complement inhibition abolished this effect.…”

Section: Models To Analyze the Efficacy Of New Therapiesmentioning

confidence: 99%

Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies

Donnou

Galand

Touitou

et al. 2012

Advances in Hematology

View full text Add to dashboard Cite

Human B-cell lymphomas, the fourth most common hematologic malignancy, are currently the subject of extensive research. The limited accessibility of biopsies, the heterogeneity among patients, and the subtypes of lymphomas have necessitated the development of animal models to decipher immune escape mechanisms and design new therapies. Here, we summarize the cell lines and murine models used to study lymphomagenesis, the lymphoma microenvironment, and the efficacy of new therapies. These data allow us to understand the role of the immune system in the fight against tumors. Exploring the advantages and limitations of immunocompetent versus immunodeficient models improves our understanding of the molecular and cellular mechanisms of tumor genesis and development as well as the fundamental processes governing the interaction of tumors and their host tissues. We posit that these basic preclinical investigations will open up new and promising approaches to designing better therapies.

show abstract

Section: Models To Analyze the Efficacy Of New Therapiesmentioning

confidence: 99%

Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies

Donnou

Galand

Touitou

et al. 2012

Advances in Hematology

View full text Add to dashboard Cite

show abstract

“…Moreover, an efficient anti-tumor response can be induced in PCNSL but this has been very poorly investigated until now. It has nevertheless been shown in a murine model of nude mice that celecoxib was able to induce a prolonged survival time (Wang et al, 2006), or in a syngeneic murine model that rituximab was able to induce tumor rejection in some animals (Mineo et al, 2008). But no study assessed the anti-tumor immune response associated with tumor rejection.…”

Section: Mouse Modelsmentioning

confidence: 99%

Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models

Galand¹,

Donnou²,

Molina³

et al. 2012

Front. Immun.

View full text Add to dashboard Cite

Diffuse large B-cell lymphomas (DLBCLs) are heterogeneous diseases growing either in nodal or extranodal locations including the central nervous system. One key issue is to decipher the prognostic value of immune cells infiltrating these tumors as DLBCLs developing in sanctuaries are more aggressive than nodal DLCBLs. Here, we summarize available data from the literature regarding the prognostic values of the different immune cell types found in these two types of human primary tumors (i.e., nodal vs brain). In nodal DLBCLs, memory T-cells and dendritic cells (DCs) densities are of good prognostic value whereas the influence of regulatory T-cells (Tregs) is less clear, in accordance with other types of cancers. Data for primary central nervous system lymphomas are very sparse for these cell types. By contrast, CD8+ cytotoxic T-cells seem to be of poor prognosis in either location. Their presence is linked to a loss of MHC expression providing a possible immune escape mechanism for these tumors. Clearly, tumor-associated macrophages are not associated to a significant prognostic value even in the brain where they highly infiltrate the tumor. Animal models indicate some specific features of lymphoma developing in sanctuaries by comparison to splenic location, with a higher infiltration of Tregs and less DCs, most likely reflecting the immunosuppressive context of these organs. All these informations illustrate the high impact of the immune system on patient outcome, encourage the pursuit of the immune environment’s analysis and of immunotherapeutic approaches.

show abstract

“…Mineo et al [32] developed a murine model to evaluate the efficiency of intravitreal and intracerebral anti-CD20 monoclonal antibody (rituximab). In this model, human CD20-transfected murine B-lymphoma cells (38C13 CD20+) were inoculated in the vitreous cavity or in the brain caudate nucleus of immunocompetent syngeneic mice.…”

Section: B-cell Murine Models For Pvrlmentioning

confidence: 99%

“…The majority of early murine models for intraocular lymphoma that followed were predominantly of T-cell lineage [26,27,28,29]. To more closely simulate human intraocular lymphoma, B-cell murine models were eventually created [30,31,32,33]. As animal models for intraocular lymphoma continue to evolve, aspects such as the tissue distribution of lymphoma infiltration and whether or not the trafficking pattern of lymphoma cells closely mimics the human disease state have offered important practical considerations.…”

Section: Introductionmentioning

confidence: 99%

Intraocular Lymphoma Models

Aronow¹,

Shen²,

Hochman³

et al. 2015

Ocul Oncol Pathol

View full text Add to dashboard Cite

Primary vitreoretinal lymphoma (PVRL) is a subtype of primary central nervous system lymphoma (PCNSL), a high-grade, extranodal, non-Hodgkin's lymphoma, predominantly of B-cell origin. PVRL is an aggressive disease with a poor prognosis. Human studies are not ideally suited for the study of intraocular lymphoma pathogenesis or treatment strategies due to the rare nature of the disease, its variable presentation, limited volume of available ocular fluids, and fragility of sampled lymphoma cells. Animal models have been critical in making progress in understanding intraocular lymphoma pathogenesis and investigating potential therapeutic strategies. Early murine models for intraocular lymphoma used intraperitoneal injection of mouse T-cell lymphomas. This was followed by intravitreal T-cell murine models. More recent murine models have used B-cell lymphomas to more closely mimic human disease. The most current B-cell lymphoma models employ a combined approach of inoculating both the mouse vitreous cavity and brain. The challenge in murine models for intraocular lymphoma lies in recreating the clinical features, disease behavior, molecular profile, systemic immunity, and the microenvironment observed in human disease. In the future, animal models will continue to be central to furthering our understanding of the disease and in the investigation of potential treatment targets.

show abstract

Using Human CD20-Transfected Murine Lymphomatous B Cells to Evaluate the Efficacy of Intravitreal and Intracerebral Rituximab Injections in Mice

Cited by 38 publications

References 42 publications

Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies

Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies

Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models

Intraocular Lymphoma Models

Contact Info

Product

Resources

About